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WEEKLY PACLITAXEL IN OVARIAN CANCER IN THE 
NORTHERN IRELAND CANCER CENTRE ￿ A SINGLE 
INSTITUTION EXPERIENCE.
Kenny LM*, McDermott U, Atkinson RJ. N.Ireland Cancer Centre, Belfast, 
UK. 
Aims: To retrospectively study the efficacy and toxicity of weekly paclitaxel 
in patients with a diagnosis of recurrent epithelial ovarian cancer who had 
previously received platinum based therapy. 
Methods: A retrospective audit was performed of 40 patients with a diagnosis 
of recurrent ovarian cancer who were treated with weekly paclitaxel. The 
median follow-up was 12 months. The objectives of the audit were to 
determine progression-free survival, toxicity and cost. Patients received 
80mg/m
2 of weekly paclitaxel and were treated to progression or 
development of grade 3/4 toxicity (NCI CTC version 2). The median number 
of cycles was 8 (range 1-34). All patients were assessed weekly. Response 
was evaluated by CT scan every 8-12 weeks and by regular measurement of 
serum Ca 125.  
Results: The mean patient age was 58 (range 44-80yrs). Eighteen patients 
(45%) were optimally debulked at time of initial surgery.  Six patients 
discontinued treatment due to toxicity before completing 5 cycles and were 
not evaluated for response. Of the remainder, 19 (48%) of patients had partial 
response/stable disease and the median progression-free survival was 8.5 
months. The mean number of previous chemotherapy regimens was 2 (range 
1-5). All patients had received previous platinum chemotherapy. 71% of 
patients had received previous paclitaxel treatment. There was some evidence 
of response in patients who had a paclitaxel (21 day regime) free interval 
under 6 months. The median time from previous paclitaxel (21 day regime) 
was 11 months, and from previous platinum was 7 months. At time of 
analysis 27 patients had died. All patients were assessed for toxicity (see 
below). There were no treatment-related mortalities. The mean cost of 
weekly paclitaxel per patient was £5730, as determined by the mean BSA. 
TOXICITY  Grade 1  Grade 2  Grade 3  Grade 4 
NEUROLOGICAL 4(10%)  6(15%)  1(2.5%  0(0%) 
ANAEMIA 8(20%)  11(27.5%)  3(7.5%)  0(0%) 
NEUTROPENIA 4(10%)  8(20%)  0(0%)  0(0%) 
THROMBOCYTOPENIA 1(2.5%)  0(0%)  0(0%) 0(0%) 
MUSCULOSKELETAL 3(7.5%)  3(7.5%)  1(2.5%)  0(0%) 
Conclusions: Weekly paclitaxel is an active and well tolerated treatment for 
platinum pretreated patients with recurrent ovarian carcinoma, regardless of 
the paclitaxel-free interval. Only 12% of patients had grade 3 toxicity, and 
there was no grade 4/5 toxicity. The overall response rate of 48% is 
favourable compared to other regimens in this patient group.  
P35 
A PHASE II STUDY OF  SEQUENTIAL CARBOPLATIN, 
PACLITAXEL AND TOPOTECAN IN PATIENTS WITH 
PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER. 
*A.E.Guppy 
1, A. Nelstrop 
1, R. Agarwal 
2 , M.J. Seckl 
2, and G.J.S.Rustin 
1
1Mount Vernon Hospital, Rickmansworth Rd, Northwood, Middlesex UK  
2Charing Cross Hospital, Charing Cross Rd, London UK.  
Objective: To evaluate the sequential use of carboplatin, paclitaxel and 
topotecan in patients with advanced, previously untreated ovarian cancer.  
Method: Patients with advanced ovarian cancer and > 1 cm residual disease 
were treated with sequential Carboplatin (AUC5 days 1 and 22), Paclitaxel 
(175mg/m2 days 43 and 64) and Topotecan (1.5mg/m2 daily for 5 days from 
days 85, 106, 127 and 148). Disease response was assessed with CA125 and 
CT at cycles 2, 4, 6 and 8 and cycles 4 and 8 respectively.  
Results: From 43 patients the median age was 61 years. Median follow-up 
was 17.3 months (range 0.76 ￿ 42.3 months). Of a total of 310 cycles of 
chemotherapy, 19 cycles were delayed (15 patients) and dose modifications 
were necessary in 14 cycles (10 patients). 34 (79%) patients received all 8 
cycles of treatment and 9 (21%) withdrew (4 due to progression and 2 due to 
toxicity). 19/28 (67.8%) evaluable patients responded according to RECIST 
and 30/36 (83.3%) patients to CA125. The best combined response was 
76.7% (33/43 patients). The response rate to individual drugs based on > 50% 
fall in CA125 was as follows: Carboplatin, 76.9% (30/39 patients),   
Paclitaxel, 65.2% (15/23 patients), Topotecan, 38.4% (5/13 patients). Three 
patients responded after failure to respond to preceeding chemotherapy. The  
median survival was 21.81 months. Median time to progression was 10.58 
months.   
Conclusion: This study demonstrates that two courses of carboplatin followed 
by sequential paclitaxel and topotecan is an active and well tolerated first line 
regime in poor prognostic ovarian cancer patients. Overall response rates are 
equivalent to combination chemotherapy and individual response rates appear 
additive. This approach should help introduction of new agents. 
P36 
NEOADJUVANT CHEMOTHERAPY AND SURGERY VERSUS 
STANDARD RADIOTHERAPY FOR LOCALLY ADVANCED 
CERVIX CANCER: A META-ANALYSIS USING INDIVIDUAL 
PATIENT DATA FROM RANDOMISED CONTROLLED TRIALS 
(RCTS).  
1LA Stewart*, 
1JF Tierney, for the Neoadjuvant Chemotherapy for Cervix 
Cancer Meta-analysis Collaboration (NACCMA Collaboration).  
1MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK. 
The NACCMA Collaboration initiated a systematic review and meta-analysis 
to assess whether combined neoadjuvant chemotherapy and surgery is more 
effective than the standard radiotherapy approach to treating locally advanced 
cervix cancer. These preliminary results are based on updated individual 
patient data from 5 RCTs, conducted world-wide, that compared neoadjuvant 
chemotherapy plus surgery with radiotherapy alone. 872 patients (96% of 
known randomised patients) and 368 deaths were included.  
Outcome HR  (95%CI) 
Absolute Effect at 5 
Years (95% CI) 
Effect 
P-value 
    
Survival 0.64  (0.52-
0.79) 
15% (from 8 to 
21%) 
0.00003 
Overall progression-free 
survival 
0.68 (0.56-
0.82) 
13% (from 7 to 
19%) 
0.00008 
Distant progression-free 
survival 
0.64 (0.52-
0.78) 
15% (from 9 to 
21%) 
0.00002 
Local progression-free survival  0.67 (0.55-
0.82) 
14% (from 7 to 
19%) 
0.00008 
      
The overall results showed a highly significant benefit of neoadjuvant 
chemotherapy combined with surgery compared to radiotherapy alone, with a 
36% reduction in the risk of death. This is equivalent to an absolute 
improvement of 15% at 5 years, increasing survival from 45 to 60%. This 
survival improvement is comparable to that seen in the concomitant 
chemotherapy and radiotherapy trials. Similar results were obtained for the 
other outcomes, although there was some statistical heterogeneity (largely 
contributed by one of the trials). There was no good evidence that patient 
subgroups defined by age, stage, histology, grade or performance status, 
benefited more or less from neaodjuvant chemotherapy and surgery. These 
preliminary results suggest that neoadjuvant chemotherapy in addition to 
surgery may be of substantial benefit in patients with locally advanced 
cervix. An updated analysis will be presented. 
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AN EVALUATION OF PATIENTS WITH PERSISTENT 
GESTATIONAL TROPHOBLASTIC DISEASE (PGTD) WITH LUNG 
METASTASES ONLY ON CHEST X-RAY OR CT SCAN OF THE 
CHEST, IS THERE EXTRA BENEFIT FROM CT SCAN? 
SY Abdallah*, J Everard, CE Ingram, R Nakielny, RE Coleman and BW 
Hancock 
Trophoblastic Disease Centre, YCR Academic Unit of Clinical Oncology, 
Weston Park Hospital, Sheffield, UK 
Background: The world Health organisation (WHO) scoring of PGTD 
depends on several factors which include the number and site of metastatic 
lesions.  CXR is used to assess lung metastases.  The aim of this review is to 
evaluate whether the CT scan of the chest affected the WHO score and 
consequently the type of chemotherapy given to those patients. 
Methods: Consecutive cases of PGTD with lung metastases detected by 
either CXR or CT scan of the chest were reviewed to assess whether the 
WHO score and hence treatment would have changed had CT scan findings 
been taken into account. 
Results: Of 75 cases reviewed, in 21 chest CT scan showed lesions which 
were either not present or different from CXR findings;  5 patients would 
have had a different WHO score if the CT scan had been used in the scoring 
process.  However none would have had a different chemotherapy regimen. 
Conclusion: Although CT scan of the chest gives more information about 
lung involvement in PGTD, it has little effect on WHO score and 
consequently on the type of chemotherapy used in the treatment of those 
patients. 
P38 
QUANTIFICATION OF ANGIOGENESIS IN PRIMARY AND 
METASTATIC EPITHELIAL OVARIAN CARCINOMAS 
*L.F. Wong Te Fong, G.K. Siddiqui, S.J. Gammell, M. Kini, 
1J.C. Crow,
 2E.S. Bamberger, W.M.N. Reid, A.B. MacLean, 
C.W. Perrett. 
Departments of Obstetrics and Gynaecology and 
1Histopathology, Royal Free 
and University College Medical School, Royal Free Campus, Rowland Hill 
Street, LONDON NW3 2PF, U.K; 
2Department of Biology, University of 
Halifa, Oranim, Tivon 36006, Israel. 
Background: Angiogenesis, the formation of new blood vessels, is of crucial 
importance for tumour growth and development of metastases.  
Objectives: The purpose of this study was to quantify a primary regulator of 
angiogenesis, vascular endothelial growth factor-A (VEGF-A), in epithelial 
ovarian carcinomas (EOC) and in omental metastases, and to determine 
whether its expression had prognostic significance with survival. 
Study design: Formalin fixed, wax-paraffin embedded ovarian tissues of 28 
primary tumours (Stages I-II, n=11; III-IV, n=17; grade 1, n=5; 2, n=13; 3, 
n=10) and 13 omental metastases were stained with a monoclonal antibody 
for VEGF-A, using immunohistochemistry. The quantification of VEGF-A 
was done according to the number of focally stained areas (each containing  ≥
10 cells) per cm
2 of the tissue section. Sections were defined positive if ≥  10 
focal areas/cm
2 were found in both the tumour area and the stroma. Statistics 
included non-parametric analysis (Mann Whitney U test) and survival 
analysis (Kaplan-Meier) with p< 0.05 considered significant. 
Results. VEGF-A was expressed in 75% (21/28) of the primary tumours and 
in all 13 (100%) of the omental specimens, with a significant difference being 
found between early (46%) and late stage (89%) primary EOC. Serous 
primary tumours as well as grade 3 ovarian cancers of any type, showed 
higher VEGF-A expression, compared to other groups. The survival rate of 
patients with VEGF-A positive tumours was significantly worse than that of 
patients with VEGF-A negative tumours in EOC, during the first five years. 
Conclusion. These findings are consistent with the hypothesis that VEGF-A 
plays an important role in ovarian cancer related-angiogenesis and tumour 
progression and may have prognostic significance in terms of metastasis and 
survival.  
P39 
CHARACTERISATION OF THE CELL CONTENT OF MALIGNANT 
ASCITES IN ADVANCED EPITHELIAL OVARIAN CANCER AND 
CLINICO-PATHOLOGICAL CORRELATIONS 
L Wall
1∗ , F Burke
2, J Smyth
1, F Balkwill
2
1 ICRF Medical Oncology Unit, Western General Hospital, Edinburgh. EH4 
2XU 
2 ICRF Translational Oncology Unit, Barts and the London School of 
Medicine and Dentistry, Charterhouse Square, London.  
Aims 
The aim of this study was to characterise the cellular population of ascites in 
human epithelial ovarian cancer, and to correlate the cellular infiltrate with 
clinico-pathological patient details. 
Methods 
Ascites was collected from patients with advanced ovarian cancer at the time 
of therapeutic paracentesis or surgery.  The cells from the ascites were used 
to make cytospins, which were stained with a panel of monoclonal antibodies 
to determine the nucleated ascitic cellular composition. 
Results 
We analysed 30 samples from 23 patients.  Ascitic cellular composition fell 
into two main patterns, predominantly tumour cells (50% of samples) and 
predominantly small lymphocytes (40% of samples).  The other patterns 
observed were predominantly fibroblasts (one sample) and predominantly 
granulocytes (two samples), despite the absence of clinical peritoneal 
infection.  We found no relationship between the proportion of the various 
cell types and histological subtype, stage at diagnosis or prognosis. 
Sequential sampling from a small number of patients suggested that response 
to chemotherapy was associated with a reduction in the proportion of tumour 
cells within the ascites.  A greater proportion of mature macrophages was 
present in the ascites of patients who responded to chemotherapy than in non-
responders (9.8% of cells versus 3.0%), although this was not statistically 
significant.  Patients on chemotherapy had significantly more fibroblasts in 
the ascites (11.7% versus 4.0%), irrespective of subsequent treatment 
response. 
Summary 
There are two predominant cellular patterns within ovarian cancer ascites: a 
predominant lymphocyte infiltrate and a predominant tumour cell infiltrate.  
The inclusion of patients at different stages of their disease and treatment into 
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patients differed.   
Within individual patients there was some suggestion that ascitic composition 
reflected treatment status and outcome.  
P40 
DETERMINING THE RESPONSE OF GYNAECOLOGICAL 
TUMOURS TO CHEMOTHERAPY USING AN MTS 
CYTOTOXICITY ASSAY IN COMBINATION WITH AN EXPLANT 
CULTURE TECHNIQUE
*Sharon A. O￿Toole, Brian L. Sheppard, Eamon P.J. McGuinness, Noreen C. 
Gleeson, Misaho Yoneda, John Bonnar. 
Trinity College Department of Obstetrics and Gynaecology, University of 
Dublin, Trinity Centre for Health Sciences, St. James￿s Hospital, Dublin 8, 
Ireland. 
The aim of this study was to use the (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) (MTS) 
assay to determine the response of malignant gynaecological tumours to 
various cytotoxic drugs.  Malignant tumour samples of the ovary, cervix and 
endometrium were taken at surgery and cultured using the explant technique. 
Cells were reseeded and incubated with various concentrations of 
chemotherapy drugs. The MTS cytotoxicity assay was carried out to ascertain 
the response to the drugs and correlated retrospectively to the clinical 
outcome. Tumours of similar stage and grade displayed heterogeneity in their 
responses to the drugs. 88 of 90 tumours (97.8%) yielded chemosensitivity 
data. Of these, 45 were evaluable for in vitro-in vivo correlations. In vitro
sensitivity was associated with clinical response in 26 of 30 patients, 
suggesting 87% prediction accuracy for sensitivity. In vitro resistance was 
associated with progressive disease or death in 14 of 15 patients, suggesting 
93% prediction accuracy for resistance. The association between in vitro and 
in vivo results for all correlations, as measured by chi-square, was highly 
significant (p<10
-6). The sensitivity [(true positives)/(true positives + false 
negatives)] of the assay was 0.96. The specificity [(true negative)/(true 
negative + false positives)] was 0.78. A chemosensitivity / resistance profile 
of the tumour is recommended prior to deciding chemotherapy treatment. 
P41 
PREDICTING PROGNOSIS IN UNRESECTABLE 
HEPATOCELLULAR CARCINOMA 
Ikram A. Burney*, Abdul Salam, Sarwar H. Orakzai, Raza H. Orakzai, 
Saleem. Sharieff. 
Department of Medicine, Aga Khan University, Karachi, Pakistan.
The treatment outcomes of HCC remain dismal. Evolving experimental 
strategies and TACE offers hope for palliation. It may be prudent to select 
patients for these procedures. A retrospective analysis was undertaken to 
study the prognostic factors in relation to outcomes of unresectable HCC. 
Consecutive patients with histologically proven HCC and admitted to the 
Aga Khan University Hospital between January 1993 and December 2000 
were the subjects of this study. A total of 348 cases were identified for 
analysis. The mean age was 57.4 ±  11.3 years. There were 251 males and 97 
females. 43% had clinically overt jaundice at presentation. The Hepatitis viral 
profile was as under: Hep. B sAg  +ve and Anti ￿ HCV +ve = 4.9%; Hep. B 
sAg +ve only = 23%; Anti-HCV +ve only  = 35.1%; Both negative = 14.9%; 
Not available = 22.1%. Laboratory investigations revealed: Hb = 11 ±  2.2 
g/dl; TLC 11.3 ±  7.7 ×  10
9/L; platelet 210 ±  134 ×  10
9/L. bilirubin 4.8 ±  7.2 
(0.1 ￿ 51.5) mg/dl; SGPT 85.8 ±  11.83 (2 ￿ 1577) IU/L; alkaline phosphatase 
240.9 ±  241.5 (34 ￿ 2750) IU/L; albumin 2.5 ±  0.7 g/dl; α  - FP 15,345 ±
59,080 (0.7 ￿ 712,600) ng/ml. α  - FP was within normal limits for 24.5% of 
patients. The Radiological examination of the abdomen revealed: unifocal / 
multifocal lesions 49.4/50.6%; mean tumor size 7.7 ±  3.7 cm; extra-hepatic 
disease 19.8%; portal vein thrombosis 20.1%. One hundred and eleven 
(31.9%) patients received specific treatment. The median survival for the 
entire group of patients was 4 months, α  - FP > 400 ng/ml, creatinine > 2 
mg/dl, encephalopathy grade 2-4 and Okuda stage III were seen to 
independently predict worse survival on a multivariate analysis.  A high α  - 
FP was the most commonly encountered (47%) poor prognostic factor. Based 
on the four adverse prognostic factors a risk-based model was constructed. 
The median survival for 0 risk factors was 24 weeks, for 1 risk factor was 16 
weeks and for 2-4 risk factors was 8 weeks (p < 0.0001). Based on this 
model, patients could be selected for the more aggressive palliative 
procedures such as TACE, and for the experimental studies. 
P42 
EAST MEETS WEST: A COMPARISON OF OESOPHAGEAL 
CARCINOMA FROM HONG KONG AND SCOTLAND USING 
COMPARATIVE GENOMIC HYBRIDISATION 
SC Stocks 
1M Sales 
2VGoldie*
3  N Pratt 
2, F Carey
11, N Kernohan
11, R 
Stuart
4, S Chung
5, A Chan
5 , D Johnston
1,  AM Thompson 
3.
Departments of Molecular and Cellular Pathology
1, Human Genetics
2 and 
Surgery and Molecular Oncology
3, University of Dundee, Dundee, DD1 
9SY; 
4Department of Surgery, University of Glasgow and 
5Chinese 
University, Prince of Wales Hospital, Hong Kong. 
Aim: Little is known of the precise sequence of genetic events that define 
malignancy or underlie the clinical course of squamous oesophageal 
carcinoma. In this study we sought to compare the range of genetic 
aberrations in two geographically distinct populations.  
Methods: Comparative Genomic Hybridisation (CGH) was performed on 
resected specimens from 41 patients:  18 cancers resected in Hong Kong and 
23 cancers resected in Scotland. The histology was confirmed as squamous 
carcinoma in all patients. For comparison and as control cancer samples the 
oesophageal cancer cell lines KYSE-30 and OE21 were used.   
Results: Genetic aberrations were detected in 14/18 Hong Kong cancers and 
18/23 Scottish cancers. Deletion of 3p, 4p and 8p were identified in 3 or more 
cancers from both geographical sites, but in addition, 5q and 18q deletions 
were identified in 3  or more of  the Scottish cancers. Similarly, while 
amplification  of 1q, 3q, 5p, 8q, 9q  and 17q were found in the Hong Kong 
cohort, additional 7p and 7q, 14q and 18p amplifications were also identified 
in 3 or more Scottish cancers. However, these additional CGH 
amplifications/deletions were also, rarely, identified in the Hong Kong 
population.  For some changes the CGH data are consistent with an 
underlying molecular pathology such as activation of myc (8q24), erb B2 
amplification (17q12), and inactivation of tumour supressors APC (5q) and 
DCC (18q). In other instances, such as amplification of 1q and deletion of 8p, 
strong candidate genes have yet to be identified.  
Conclusion: In keeping with the known common aetiologies, these data 
obtained using CGH suggest that squamous carcinoma of the oesophagus has 
a similar spectrum of amplifications and deletions in the East and West 
P43 
IS POOR SURVIVAL FROM OESOPHAGEAL AND GASTRIC 
CANCER SURGERY DUE IN TO INADEQUATE STAGING? 
AM Thompson*, Department of Surgery and Molecular Oncology, 
University of Dundee, DD1 9SY for the Scottish Audit of Gastric and 
Oesophageal Cancer 
Aim: To assess the staging of patients undergoing gastric or oesophageal 
resection. 
Methods: The population-based Scottish Audit of Gastric and Oesophageal 
Cancer (SAGOC) collected data prospectively from every patient diagnosed 
with oesophageal or gastric cancer in Scotland over a 2 year period (to 
September 1999). Follow up was continued for a minimum of 1 year after 
diagnosis. Data was analysed by the Scottish Cancer Intelligence Unit of the 
National Health Service.  
Results:  1302/3292 (39.5%) patients identified over the 2 year period 
underwent surgery; 1006 had pathology data on a resected specimen. 
Resection margins were involved in 114/371 (31%) oesophageal resections, 
44/156 (29%) junctional resections, and 95/479 (20%) gastric cancer 
resections, the majority of whom had pT3 or pT4 cancers. The radial 
(circumferential) margin was involved in 68% of patients with resection 
margin involvement. For oesophageal and junctional cancers, this was not 
related to the surgical approach used. Three quarters (180/240) of patients 
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with multiple margin involvement). Given that the one year survival for the 
patients who underwent operation was 54%, these data suggest that operative 
intervention was inappropriate in upto a third of patients who underwent 
surgery.  
Although 93% patients underwent CT of chest and abdomen prior to 
oesophagectomy with curative intent, only 30 (8%) underwent endoscopic 
ultrasound (EUS). For junctional cancers, 90% had an abdominal CT and 
85% a CT chest but laparoscopy was used in only 44% and EUS in 6%. For 
gastric cancer, 71% underwent abdominal CT, 33% laparoscopy and 4% 
EUS. Preoperative staging was therefore incomplete in a substantial 
proportion of patients. 
Conclusions: To avoid inappropriate (non-curative) surgery, improvements 
in the provision (for EUS) and utilisation (for laparoscopy) of staging tests 
and their correct interpretation (of,  for example, CT scans) will be required. 
These data suggest that major changes in clinical practice are needed to 
improve the selection of patients for curative oeosphageal and gastric 
surgery. 
P44 
OESOPHAGEAL CANCER CELL LINES APOPTOSE FOLLOWING 
TRANSFECTION WITH WILD TYPE P53. 
Oglesby SD
1*, Hupp TR
2, Thompson AM
1. Departments of Surgery & 
Molecular Oncology
1, and Molecular & Cellular Pathology
2, University of 
Dundee, Dundee. DD1 9SY. 
Introduction. Most patients with oesophageal cancer do not undergo surgery 
and many are treated with radiotherapy. We have previously reported that the 
oesophageal cancer cell lines OE19, OE21, and OE33 have p53 mutations, 
and that these mutations lead to resistance to this treatment modality 
(Oglesby et al, BCRM 2001). We sought to assess the effect of restoring 
functional p53 in these cell lines by means of liposome mediated transfection 
of plasmid containing wild type p53. 
Methods. SV53 is a plasmid which constitutively expresses wild type p53 via 
an SV40 promoter. OE19, OE21, OE33 were each grown in 75cm
2 tissue 
culture flasks until 70% confluent at which point they were transfected with 
SV53. TFX-50 (Promega) a liposomal transfection reagent was used to 
transfect 15µ g plasmid in each flask. Cells were collected by trypsinisation at 
6 hourly intervals from 0 to 24 hours. OE19 and OE21 have p53 mutations 
which lead to production of a truncated protein. Expression of full length 
protein in these cell lines can therefore be assessed by western blot analysis. 
Assessment of apoptosis was performed by flow cytometry using propidium 
iodide.
Results. In the OE19 and OE21 cell lines, expression of full length p53 was 
detected at 6 hours and was maximal at 18 hours. All cell lines showed 
increasing induction of p21 over the 24 hour time course. Apoptosis was 
identified at 6 hours, and was maximal at 24 hours. 
Discussion. Our study shows that it in cell lines which are resistant to 
ionising radiation, transfection with wild type p53 is very effective at 
inducing programmed cell death. Given that the p53 mutation rate in 
oesophageal cancer may be as high as 84% (Robert et al, Carcinogenesis 
2000), and that most oesophageal cancers exhibit limited sensitivity to 
conventional treatment, restoration of functional p53 by transfection may 
provide a useful therapeutic strategy in this disease. 
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P 53 MUTATION RATE IN OESOPHAGEAL CARCINOMA IS 
HIGHER THAN GENERALLY ACCEPTED
Oglesby SD
1*, Warbrick E
1, Johnston DA
2, Dillon JF
2, Munro AJ
1, Hupp 
TR
2, Thompson AM
1. Departments of Surgery & Molecular Oncology
1, and 
Molecular and Cellular Pathology
2, University of Dundee, Dundee. DD1 
9SY. 
Introduction. p53 is a key regulator of cellular response to radiation and 
cytotoxic drugs. The currently accepted p53 mutation rate in oesophageal 
carcinoma is in the region of 50% (Beroud et al, Nuc Acid Res 1998). Until 
recently, sequencing has been the gold standard for identifying inactivating 
mutations. However, sequencing can perform poorly when used to analyse 
material with a mixture of cell types such as found in tumour biopsies. The 
functional yeast assay (FYA) is a relatively new method of evaluating p53 
mutations and outperforms sequencing when used on biopsy material. Duddy 
et al (J Mol Diagn 2000) found that sequencing p53 exons 5-8 identified only 
54% of mutations detected by FYA in breast cancer. Robert et al 
(Carcionogenesis 2000) analysed 50 squamous and 6 adenocarcinomas of the 
oesophagus using FYA and report a mutation frequency of 84%. However, in 
most western societies, the frequency of adenocarcinoma now exceeds 
squamous. We sought to identify the frequency of p53 mutations in 
carcinoma of the oesophagus in a typical western population. 
Methods. Tumour biopsies were obtained from 30 consenting patients with 
oesophageal carcinoma. The biopsies were assessed for p53 mutations using 
the FYA. Confirmation of p53 mutation was sought by sequencing plasmid 
recovered from single yeast colonies. The histological tumour type was 
recorded. 
Results. 22 of 30 tumours were adenocarcinomas, all were identified as 
containing mutant p53 by FYA. The remaining 8 tumours were squamous 
and 4 of these (50%) were mutant. The overall p53 mutation rate was 87%, 
all mutations were confirmed by plasmid sequencing.  All mutations were 
within the core DNA binding domain of p53. 
Discussion. Our study confirms a high p53 mutation frequency in 
oesophageal carcinoma and also shows that this applies to adenocarcinomas. 
Previous studies attempting to correlate p53 status with treatment 
responsiveness have been inconclusive, which may in part be due to 
underreporting of p53 mutations.  
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ORAL CAPECITABINE IN METASTATIC COLORECTAL CANCER 
(CRC)  
B.Basu*, J.Abraham, V.R.Bulusu, K.Grant, M.Corcoran, J.Shaw, R.Harris, 
P.Corrie, C.B.Wilson, Oncology centre, Addenbrooke￿s hospital, Cambridge, 
UK CB2 2QQ. 
Introduction: Capecitabine is one of oral 5FU prodrugs, which is activated 
preferentially in the tumour. We present the ￿real life￿ data in patients (pts) 
with metastatic crc. 
Aim: To assess the overall response rates and toxicity profile of oral 
capecitabine in pts with metastatic crc. 
Material and Methods: 18 pts (9 males, 9 females) with metastatic crc were 
treated with oral capecitabine at 2.5gm/m
2 /day for 14 days, cycle repeated 
every 3 weeks. Mean age 64 years, WHO performance status 0-2. All had 
normal haematology and renal function. No dose corrections were made for 
hepatic dysfunction. 18 pts are evaluable for toxicity and 17 for response. 
Overall response rate (ORR), complete response (CR), partial response (PR) 
and stable disease (SD) were assessed using WHO criteria and toxicity as per 
the common toxicity criteria. Survival was calculated from the date of first 
cycle. 
Results: A total of 98 cycles were administered with median of 5. 1 CR, 4 
PRs ( ORR=29%) and SD in 9 (53%) were noted. Only one pt progressed on 
treatment. Grade 3 toxicity was noted in 44% of pts, 27% palmar-plantar 
erythema (PPE), 17% fatigue, 5% mucositis and diarrhoea. 1 pt required 
hospital admission for management of toxicity. 33% had dose reductions to a 
mean of 84% of the total projected dose. No treatment related deaths were 
recorded.  
Conclusions: Oral capecitabine is well tolerated in pts with metastatic crc 
with an ORR of 29%. The major dose limiting toxicities were PPE and 
fatigue. No differences in the toxicity pattern between the sexes were 
observed. PPE responded to dose reductions/schedule alterations/pyridoxine. 
P47 
EXTERNAL BEAM RADIOTHERAPY (EBRT) IN LOCALLY 
ADVANCED PANCREATIC CANCER (LAPC): IPSWICH 
EXPERIENCE  
V.R.Bulusu*, E.McEwan, L.Smith, A.J.Poynter, J.Crosbie, O.Allen, 
T.J.Podd, Suffolk Oncology Centre, Ipswich Hospital, Heath Rd, Ipswich, 
UK IP4 5PD. 
Introduction:  The role of radiation in LAPC is not clearly defined. 
Gemcitabine has been the standard chemotherapy for pancreatic cancer. We 
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Aim: To assess the overall survival and toxicity in patients who have 
received EBRT for LAPC.  
Material and Methods: 21 patients (pts) who have received EBRT for 
LAPC were included in this study. Pancreatic cancer was diagnosed either by 
histology and/or CT criteria in 13 males and 8 females with a mean age of 63 
yrs |(range 51-75years). All had WHO performance status 0-2. Prophylactic 
ranitidine or lansaprazole was prescribed from the start of EBRT. Majority of 
the pts received chemotherapy  5FU or gemcitabine either adjuvant or on 
progression.  
Radiation Treatment Protocol: Pts were treated with either a parallel opposed 
fields (n=6) or 3 field CT plan (n=15) using 6/16 MV photons. Radiation 
dose was specified to the ICRU 50 recommended reference point. CT 
imaging was performed using either a Siemens Somatom CT scanner (n=18, 
slice width=10mm) or a GE Light Speed CT scanner (n=3, slice 
width=5mm). Fifteen pts were planned using the Nucletron PLATO 
treatment planning system. 
Results: All 21 pts were assessable for both toxicity and survival. Only 1/21 
failed to complete EBRT due to grade 3 gastrointestinal toxicity. Mean and 
median EBRT doses 44.5 and 50Gy (95% CI 40.5-48.5). Toxicity data: 
Nausea 100%, emesis requiring treatment 45%, diarrhoea 20% indigestion 
10% and 5% weight loss. Kaplan-Meier survival estimates for 6, 9, 12 and 24 
months are 0.90, 0.75, 0.55 and 0.22 respectively. 6/21pts are alive at 
5,11.5,11.5,14.5,22 and 27 months from the date of diagnosis. There were no 
gut perforations or treatment related deaths. No Grade 4 acute toxicity was 
recorded. 
Conclusions: EBRT for LAPC is well tolerated with acceptable toxicity. 
EBRT may have a role in the management of pts with LAPC. Recent 
advances in conformal/intensity modulated radiotherapy may help to achieve 
a better therapeutic ratio and may allow further dose escalation. Future trials 
in pancreatic cancer should critically evaluate the role of radiotherapy in 
improving local control and possibly overall survival.  
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BIOPSY OF A BIOPSY: VALIDATION OF IMMUNOPROFILING IN 
GASTRIC CANCER BIOPSY TISSUE MICROARRAYS.
Christian Gulmann*, David Butler, Elaine Kay, Antoinette Grace, Mary 
Leader.  
Department of Pathology, Beaumont Hospital and Royal College of 
Surgeons, Dublin, Ireland.
Background and aim: Tissue microarrays offer an efficient way of examining 
a large number of tumour cases on a single glass slide. A major concern, 
however, is tumour heterogeneity. Also, the use of tissue microarrays in 
biopsy material is unexplored. The purpose of the present study was to assess 
the possibility and validity of arraying three 0.6-mm cores per case in 
endoscopic gastric cancer biopsies for immunophenotyping.  
Materials and methods: Thirty-eight cases were studied with 
immunohistochemical staining for p53, CD44v6 and vascular endothelial 
growth factor. All play a role in the progression of gastric cancer and were 
chosen to cover a spectrum of complexity of staining interpretation as well as 
staining different cellular substructures. p53 was interpreted as positive or 
negative whereas the two other stains were graded for intensity and extent 
with chosen cut-off points for overall positivity/negativity. With triplet cores 
￿majority decisions￿ (i.e. two cores versus one) were carried out in the case of 
a discrepancy between cores from the same case. Full tissue sections were 
compared with triplet core-tissue microarrays.  
Results: Thirty-six cases contained three cores with tumour, one case 
contained two cores with tumour and one case contained only a single core 
with viable tumour and was excluded. Three further cores had been lost from 
3 separate cases on the sections for immunohistochemistry. Concordance 
rates and kappa-values were 97% and 0.94 for p53, 92% and 0.77 for 
CD44v6 and 97% and 0.77 for vascular endothelial growth factor. p53 
immunohistochemical staining yielded the strongest result with only 1/37 
mismatches, whereas CD44v6 showed 3/37 mismatches.  
Conclusion: Tissue microarray with three cores per case is a feasible and 
valid way of studying biopsy material. The small depth of tissue in cores 
from biopsies necessitates all cores being arrayed flush with the face of the 
recipient wax block for maximising number of sections available. It is 
therefore impractical to array more than 120-150 cores per block.  
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A PROSPECTIVE CASE CONTROL ANALYSIS OF 
CYCLOOXYGENASE-2 EXPRESSION IN BARRETT￿S 
OESOPHAGUS PATIENTS 
J.Jolly
1*, L.J.Hardie
1, M.F. Dixon
2, C.P.Wild
1.
1Molecular Epidemiology Unit, School of Medicine, University of Leeds and 
2Department of Pathology, Leeds General Infirmary, Leeds LS2 9JT. 
One of the greatest risk factors for the development of oesophageal 
adenocarcinoma (AO) is the presence of Barrett￿s oesophagus (BO). This 
condition is characterised by the replacement of the normal squamous 
epithelium of the oesophagus with a specialised, columnar type.  Molecular 
alterations which occur during the development of BO, may serve as 
biomarkers to assess the risk of AO development in this patient group (Bani-
Hani et al., 2000; JNCI 92; 1316-1321). The prostanoid synthesizing 
enzyme, cyclooxygenase-2 (COX-2) is reported to be upregulated in BO and 
AO, and epidemiological studies link this enzyme to AO development 
through the observed protective effect of non-steroidal anti-inflammatory 
drug use. 
The aim of this study was to examine the potential predictive utility of COX-
2 expression as a molecular marker of AO development in BO patients.  
A total of 307 BO patients were enrolled into an endoscopic surveillance 
cohort at Leeds General Infirmary between 1984-1995. For each incident 
case of adenocarcinoma, four control patients were matched for duration of 
follow up, age, sex, and length of columnar epithelium at recruitment. 
Following ethical approval, biopsies obtained from cases at recruitment and 
at diagnosis of AO, together with matched biopsies from control patients 
were stained for COX-2 expression using conventional 
immunohistochemistry techniques. Slides were assessed in a blinded fashion 
by a pathologist using a semi-quantitative scoring system. 
COX-2 was expressed in all of the AO tumours (N=15) arising within the 
cohort.  However, biopsies taken at recruitment from the same incident AO 
cases were no more likely to be COX-2 positive (40%) than those of matched 
control patients (55%).  However, the number of biopsies which expressed 
COX-2 increased (55% - 80%) with duration of follow-up in control BO 
patients. In addition, a greater proportion of follow-up biopsies stained for 
COX-2 in both surface and glandular compartments compared with 
recruitment biopsies in these patients.  
In this study, no difference was observed in COX-2 expression between cases 
and controls at recruitment, suggesting that COX-2 is not informative at 
identifying BO patients at increased risk of progression to AO. However, that 
COX-2 expression was observed to increase and change in localisation with 
time, is suggestive of an association with disease development and warrants 
further investigation.  
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INCREASE IN GENE AND PROTEIN EXPRESSION OF GASTRIN, 
CCK2R, MMP-2 AND TIMP1 IN BARRETT’S COMPARED TO 
PAIRED NORMAL SAMPLES
JC Harris
*1, RA Dean
1, PA Clarke
1, A Awan
1, J Jankowski
2, SA Watson
1
1Academic Unit of Cancer Studies, QMC, University Hospital, Nottingham 
NG7 2UH; 
2Department of Medicine, University of Birmingham, Edgbaston, 
B15 2TH
Background and Aims: Barrett￿s Oesophagus is a pre-malignant condition 
of the lower oesophagus caused by prolonged gastro-oesophageal acid reflux 
and characterised by a metaplastic change from normal squamous to 
columnar intestinal-type epithelium. The aim of this on-going study was to 
assess levels of gastrin, cholecystokinin 2 receptor (CCK2R), and a variety of 
matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases 
(TIMPs) in normal and Barrett￿s biopsy samples and two established 
oesophageal cell lines. 
Methods:  Real-time PCR was used to investigate the gene expression of 
gastrin, CCK2R, MMP-2, -9, MT1-MMP, TIMP1 and 2, in the normal and 
Barrett’s biopsy samples (n=9) as well as the cell lines OE19 (oesophageal 
adenocarcinoma, pathological stage III) and OE33 (oesophageal Barrett’s 
metaplasia, pathological stage II). Immunohistochemistry was used to 
investigate progastrin and CCK2R at the protein level in all samples. 
Results: The grade III adenocarcinoma cell line OE19, was shown to express 
relatively higher levels of gastrin, MMP-2 (P=0.05) and TIMP1 (P=0.0413) 
at the gene level compared to the Barrett’s metaplasia cell line, OE33. These 
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(P=0.0423), total CCK2R (P=0.0406), MMP-2 (P=0.031) and TIMP1 
(P=0.041) gene expression was observed in Barrett￿s compared to normal 
epithelium. With regard to CCK2R, immunohistochemistry illustrated a 
stepwise increase in levels of the intron 4 splice variant (CCK2Ri4sv) 
isoform of the receptor, as normal tissue progressed to Barrett￿s (P=0.045).  
Conclusion: The mRNA levels of gastrin, MMP-2 and TIMP1 have been 
shown to be higher in the adenocarcinoma cell line OE19, compared with the 
Barrett’s metaplasia cell line OE33. Similar results were shown in the 
Barrett￿s metaplasia biopsies compared to their paired normal samples, 
including an increase in CCK2R gene expression. An increase in CCK2Ri4sv 
at the protein level has also been shown. It is hence concluded that 
progression to Barrett￿s Oesophagus could be associated with an increase in 
MMP, gastrin and CCK2Ri4sv expression. 
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GENE EXPRESSION AND CELL CYCLE ANALYSIS OF 
COLORECTAL CANCER CELL LINES EXPOSED TO 5FU AND 
5FDURD 
Sandra Easdale
*1, Paul. Clarke
1, Jenny Titley
1, Richard Wooster
2 and Paul 
Workman
1
1Cancer Research UK, Centre for Cancer Therapeutics, Institute of Cancer 
Research, 15 Cotswold Road, Sutton 
2Institute of Cancer Research, 15 Cotswold Road, Sutton and the Sanger 
Centre, Cambridge 
Although, 5FU is the mainstay treatment for colorectal cancer, its precise 
molecular mechanism of action is undefined. It is already known that 5FU 
treatment results in inhibition of thymidylate synthase and misincorporation 
of its metabolites into both DNA and RNA. Microarray technology allows for 
the measurement of global gene expression and is poised to revolutionise the 
discovery and use of new anticancer agents. This project involved the 
analysis of gene expression patterns in three human colorectal cancer cell 
lines exposed to 5FU and one of its important metabolites 5FdUrd. 5FU was 
chosen for this analysis due to its complex mechanisms of action that were 
expected to challenge the microarray technology and there has also been a 
long standing interest in the mechanism of action of 5FU and thymidylate 
synthase inhibitors within our Institution. The three cell lines were exposed to 
five times their IC50 concentrations of 5FU or 5FdUrd and cell cycle 
distribution analysed over 2-72 hours. Messenger RNA was also extracted 
from cells exposed to the same drug concentrations and time course. The 
mRNA was labelled with fluorescent dyes (Cy3 and Cy5) using reverse 
transcription and hybridised to 5808 cDNA clones arrayed on glass slides. 
The array slides were prepared in-house and encompass known genes and 
ESTs known or suspected to be associated with cancer, for example cell 
adhesion genes, apoptosis genes and cell cycle genes.  Cell cycle analysis 
showed that each cell line was arrested in the G1 phase of the cell cycle and a 
depletion of cells in S phase was also found. Each cell line was affected to a 
varying degree. For example, HCT116 cells demonstrated an accumulation of 
cells in late G1/early S phase at 4 hours post treatment, whereas both HT29 
and SW480 cells did not exhibit this effect until between 16 and 24 hours. 
Both 5FU and 5FdUrd treatments cause similar effects upon the cell cycle in 
these three cell lines. Thymidine, but not uridine protected HT29 cells from 
the effects of 5FU and these observations indicate that the 5FU is acting via 
thymidylate synthase inhibition within these cell lines. Microarray analysis of 
5FU and 5FdUrd treated cells demonstrated that each cell line had its own 
distinctive pattern of gene expression. A considerable number of genes 
exhibited altered expression, either increased or decreased relative to control 
levels. In excess of 500 genes were altered over the entire course of the 
experiment within each cell line.  No evidence of alteration of genes involved 
in pyrimidine metabolism or DNA/RNA metabolism was found. From the 
array analysis both 5FU and 5FdUrd treatment appear to affect similar types 
of genes, for example those involved in the regulation of the cell cycle. No 
evidence for p53 induced gene expression could be found in wild-type p53 
HCT116 cells contrary to published data at higher 5FU concentration. The 
analysis of our data is still ongoing; however preliminary results have 
indicated that several genes involved in the regulation of the cell cycle (for 
example RB, CIP2/KAP1 and CDK8) have altered expression. 
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PRELIMINARY RESULTS OF A PHASE II PILOT STUDY OF 13-
CIS-RETINOIC ACID WITH GEMCITABINE IN PATIENTS WITH 
UNRESECTABLE PANCREATIC OR CHOLANGIOCARCINOMA. 
Michael A. *
1 Maraveyas A
2, Lofts F
1; 1-St. George￿s Hospital London 
SW17 0QT, 2-The Princess Royal Hospital Hull HU8 9HE 
Patients with locally advanced or metastatic pancreatic cancer have a poor 
prognosis and suffer severe disease related symptoms. The median survival 
without any treatment is approximately 3 months. The one treatment that has 
proved beneficial and well tolerated is chemotherapy. Comparison between 
Gemcitabine and weekly 5FU gave a 5-week improvement in median 
survival. Gemcitabine also increases clinical benefit response as defined by 
improvement in pain, weight loss and performance status. Unresectable 
cholangiocarcinoma is a chemoresistant cancer with extremely poor 
prognosis. Patients with this condition should be considered candidates for 
inclusion in clinical trials. 
The retinoids are derivatives of vitamin A that are known to affect tumour 
cells, can inhibit growth as well as induce differentiation and apoptosis. Pre-
treatment of pancreatic adenocarcinoma cells with 9-cisRA followed by 
Gemcitabine resulted in a strong increase in apoptosis (Pettersson F, 2001: 
Pancreas, Vol.23, p.273). 13-cis retinoic acid has been studied in many solid 
tumours with some promising results in glioma and renal cell carcinoma 
(Aisner J. 2000, ASCO Abstracts No1416, Jaeckle 2000, ASCO Abstracts No 
629).  
We are conducting a study of Gemcitabine in combination with 13-cis 
retinoic acid in locally advanced or metastatic carcinoma of pancreas or 
cholangiocarcinoma. Gemcitabine is given on day 8,15 and 22 at a dose of 
1000mg/m
2and 13-cis RA is given orally, day 1 to 14 at dose of 1mg/kg. To 
date eleven patients have been recruited  (2F/9M), median age 63 (range 45-
78) and median Karnofsky PS 93% (90-100%). Out of 20 cycles given only 
one case of grade 3 toxicity has been reported with thrombocytopaenia . The 
recruitment of this well tolerated regimen continues. 
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COLORECTAL CANCER CELL DEATH IN PATIENTS RECEIVING 
NEOADJUVANT IMMUNOTHERAPY ￿ PRELIMINARY RESULTS 
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Scholefield
1
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1 and Department of Immunology
2;
University Hospital Nottingham, NG7 2YH; Academic Department of 
Clinical Oncology
3, Nottingham City Hospital, Nottingham, NG5 1PB.
Background: 105AD7 is an anti-idiotypic antibody that mimics CD55 found 
on 80% of colorectal cancer cells, and has shown effective antigen-specific 
immune responses in immunised colorectal cancer patients. We assessed 
apoptosis in this group of patients in a randomised control trial. 
Methods: Patients with colorectal cancer were randomised to treatment with 
neo-adjuvant 105AD7/Alum, or 105AD7/BCG or control, with the treatment 
arms immunized 2-3 weeks prior to surgery then at regular intervals 
thereafter. Resected tumour specimens underwent 3-colour flow cytometric 
analysis with Apo2.7 and Anti-Caspase-3 antibodies to detect apoptosis.  
Results:   12 patients receiving 105AD7/Alum, 14 who received 
105AD7/BCG, and 16 control patients had their adenocarcinomas analysed 
(Dukes A-6, B-15, C1-16, C2-4, D-2).  There were increased levels of 
Apo2.7 in patients receiving 105AD7/Alum compared to controls, but with a 
wide range of data. Proliferation was also reduced in the treated group. 
Medians CONTROL  105AD7/Alum 
p
value 105AD7/BCG 
p
value 
Tumour Apo2.7  13.5  20.6  .66  11.8  .51 
Tumour Anti-
Caspase-3 2.56  2.79  .98  1.22  .98 
Tumour Ki-67  2.76  2.12  .87  2.3  .88 
Lymphocyte 
Apo2.7 .43  .36  .39  .51  .48 
Lymphocyte 
Anti-Casp-3 .03  .02  .31  .02  .34 
Lymphocyte 
Ki-67 .13  .16  .35  .16 .31 
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control patients showed specific T cell proliferation responses, however only 
2 of these patients responded to the initial pre-operative dose with both 
having high rates of tumour apoptosis. The other patients responded after 
their fourth booster. 
Conclusion:  Increased levels of apoptosis were seen in colorectal cancer 
patients receiving 105AD7/Alum compared to controls, however this sample 
is too small at present to draw any firm clonclusion, but recruitment is 
presently ongoing. This reflects the difficulty in measuring apoptosis in 
clinical practice where variable factors result in high background values. 
However 105AD7/Alum does induce good cellular immune responses that 
may result in improved clinical response in colorectal cancer patients. 
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Introduction: Gemcitabine (Gem) is active against a broad range of tumour 
types. Preclinical models suggest synergy between Gem and Cisplatin (Cis), 
and in phase II trials this combination has activity in NSCLC, head & neck 
cancer and bladder cancer. This study aims to assess its activity in 
oesophageal cancer. 
Methods: Patients with histologically proven, bidimensionally measurable, 
locally advanced or metastatic oesophageal carcinoma (squamous or 
adenocarcinoma), aged >18yrs, with a performance status 0-2 and life 
expectancy > 3 months, who were able to give informed consent were 
eligible. A total of 48 patients are required to differentiate between response 
rates of > 60% and < 40% with a power of 80% at the 5% significance level. 
Treatment: Treatment with Gemcitabine 1250 mg/m
2 on days 1 and 8, and 
Cisplatin 75 mg/m
2 on day 1 of a 21 day cycle was given. Gemcitabine dose 
was reduced by 50 % if, on the day of treatment, ANC 0.5 ￿ 0.9 x 10
9/L or 
plts 50 ￿ 99 x 10
9/L. Treatment was withheld if the ANC was < 0.5 and plts < 
50. The Cisplatin dose was split over 2 days if calculated creatinine clearance 
was 40 ￿ 60 ml/min, and omitted if  < 40 mls/min. Treatment was stopped in 
the event of grade 3/4 peripheral neuropathy. 
Results: Due to concerns over toxicity, an interim analysis was performed 
after 19 pts (M:F = 16:3. Median age = 60yrs (range 38 ￿ 79 yrs)) were 
entered. One patient had received 6 cycles of Cis/5FU as adjuvant treatment 
12 months earlier. Median number of cycles completed = 4 (range 1 ￿ 6), 
with 11pts completing at least 4 cycles and 6 pts completing 6 cycles. 
Haematological toxicity in cycle 1 was as follows: Neutropenia ￿ grade 4 in 2 
pts; grade 3 in 6 pts; Thrombocytopenia ￿ grade 3 in 2 pts; Anaemia ￿ grade 
4 in 1 pt (not treatment related). In all cycles, 13 pts had at least grade 3 
haematological toxicity, but there were no episodes of neutropenic sepsis or 
complicated thrombocytopenia. The most common non-haematological 
toxicities were nausea & vomiting (grade 3/4 in 8 pts despite 5HT3 
antagonist and steroid premedication) and lethargy (grade 3 in 5pts). 4 pts 
discontinued therapy due to toxicity. Partial responses were observed in 7 pts, 
with stable disease in a further 6. 
Conclusion: This level of toxicity and dropout rate was felt to be 
unacceptable for a palliative treatment at the current doses. In evaluable pts a 
response rate of 41% was achieved which is comparable to Cis/5FU. In view 
of this, the trial will continue to its recruitment target with a reduced Gem 
dose and an altered dose modification schedule.  
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A WEST OF SCOTLAND AUDIT OF SHORT-COURSE PRE-
OPERATIVE RADIOTHERAPY FOR OPERABLE RECTAL 
CANCER
V Hughes* and AC McDonald, Beatson Oncology Centre, Western Infirmary 
Glasgow G11 6NT, UK.  
Introduction  Short-course (25Gy in 5 fractions, over 1 week) pre-operative 
radiotherapy (pre-op RT) reduces local failure and may improve survival in 
patients (pts) with operable rectal cancer, however it is not without toxicity. 
This audit was performed to determine the use of short-course RT in the 
Beatson Oncology Centre and to identify whether some pts may be better 
served by alternative approaches.  
Methods  A retrospective case sheet audit was undertaken of pts receiving 
short course pre-op RT for rectal cancer between June 1999 and December 
2000. Patients were identified from the computerised RT booking system. 
Information from clinical notes and pathology reports was reviewed.  
Results  Forty-seven pts received short-course pre-op RT during the period 
studied, with data available on 44pts. Five pts received treatment within the 
MRC CR07 study (comparing short course pre-op RT with immediate 
resection); 2 further pts entering CR07 drew immediate surgery during the 
period audited. Baseline staging comprised clinical tumour assessment, 
abdomino-pelvic CT (38pts), CXR & liver ultrasound (4pts) and MRI (1pt). 
Eleven patients underwent trans-rectal ultrasound (uT2=2, uT3= 7, uT4=2). 
Clinical details were poorly documented, with rectal examination findings 
and tumour mobility detailed in only 27 and 20 pts respectively. Of these 20 
pts, 8 were said to have fixed tumours at the time of referral. Treatment was 
delivered by 9 oncologists, however of these only 3 each treated more than 2 
pts. Eight clinicians used a planned volume, however 1 used opposed AP-PA 
fields. All 44 pts completed treatment and underwent tumour resection, 
potentially curative in 41 cases. Median time to resection was 4 days, (range 
1-13) after completion of RT. Pathologic staging identified Duke￿s A 8pts 
(18%), B 17pts (39%), C 16pts (36%) and D 3pts. Eleven pts (25%) had 
involvement (≤ 1mm clearance) of the circumferential resection margin 
(CRM). In 17pts (38%) there was no documentation of histopathologic 
findings in the case-sheet. There were no post-op (<30 days) deaths, but 
treatment toxicity and post-op complications were poorly recorded.  
Conclusion Of 9 oncologists using short-course pre-op RT, the majority 
treated only one or two cases. A number of (Duke￿s A) patients at low risk of 
local failure received pre-operative treatment. The 11 pts with locally 
advanced disease and CRM involvement may have been better served by pre-
op chemoradiation. Accrual of pts into clinical trials was low. Documentation 
of clinical findings, treatment toxicity and outcome was poor and might 
arguably be improved with tumour site-specialisation and multi-disciplinary 
team working.  
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Background: Epidermal growth factor receptor (EGFR) signaling has been 
implicated in the proliferation and survival of cancer cells. ZD1839 (￿Iressa￿) 
is an orally active selective inhibitor of EGFR signaling. Single-agent clinical 
trials have demonstrated promising antitumor activity in several tumor types. 
Combination studies with cytotoxic drugs, including 5-FU, have indicated 
additive or synergistic activity. Methods: Patients with metastatic colorectal 
cancer, not selected for EGFR status and treatment-naive in the metastatic 
setting, were treated in this two-part study of escalated intermittent and 
continuous schedules of ZD1839 plus 5-FU/LV administered utilizing the 
Mayo regimen (370/20 mg/m
2 daily for 5 days). Results: In part 1, 20 
patients were randomized to intermittent ZD1839 plus 5-FU/LV on one of 
two schedules: (A) ZD1839 on days 1-14, 5-FU/LV on days 8-12 (cycle 1) 
and days 36-40 (cycle 2); or (B) 5-FU/LV on days l-5 (cycle l) and days 29-
33 (cycle 2) plus ZD1839 on days 22-35.  Intermittent ZD1839 dose-
escalation (250/400/500 mg) was carried out in cohorts of 6-12 patients. In 
part 2, continuous ZD1839 was administered at 500 mg, the highest safely 
administered dose in part 1, with 5-FU/LV on days 8-12 (cycle l) and days 
36-40 (cycle 2). One patient had dose-limiting G3 ataxia at 500 mg on the 
intermittent schedule, and one patient had dose-limiting G3 skin rash at 
500 mg on the continuous schedule. G3/4 toxicities included neutropenia (9 
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Pharmacokinetic studies indicate no significant change in mean exposure to 
either ZD1839 or 5-FU/LV when they are given in combination. One patient 
had a complete response; 5 partial responses were observed and 12 patients 
had durable stable disease. The overall median (range) duration on study was 
70 (13-347) days. Conclusion: This combination of continuous ZD1839 with 
Mayo regimen 5-FU/LV is well tolerated and demonstrates promising 
activity. Further trials with ZD1839 in colorectal cancer are now planned or 
underway. 
￿Iressa￿ is a trademark of the AstraZeneca group of companies. 
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ENDOSCOPIC PALLIATIVE TREATMENT:  
ANALYSIS OF 948 CONSECUTIVE PATIENTS IN THE 
SCOTTISH AUDIT OF GASTRIC AND 
OESOPHAGEAL CANCER.  
AM Thompson*, R Stuart for the Scottish Audit of Gastric and Oesophageal 
Cancer, University of Dundee, DD1 9SY. 
Aim: To document current practice, seek variations in practice and record 
complications from Endoscopic Palliative Treatment (EPT) in a population 
cohort of patients with oesophageal or gastric cancer. 
Methods: Data was collected from every patient diagnosed with 
oesophageal, junctional or gastric cancer in Scotland over a 2 year period (to 
September 1999) with subsequent minimum 1 year follow up. Ethical consent 
was obtained for the study. 
Results: EPT was given to 948/3,293 patients, predominantly with 
oesophageal or junctional cancers. Stent alone (506 patients) or LASER alone 
(117 patients), combination approaches including radiotherapy (188 patients) 
or chemotherapy (134 patients) were used. The majority of patients (>65%) 
had normal physical activity / only strenuous activity restricted before 
undergoing EPT. The consultant looking after the patient considered stents 
were used appropriately for 95% of patients (for grade 3 or 4 dysphagia) and 
LASER in 83% of patients (for grades 1, 2, 3 dysphagia). There was 
significant variation in delivery of EPT by healthboard of residence (chi 
square test, P<0.001), but not by deprivation quintile. 
Complications, recorded in 221/948 patients (23%), were associated with 
multiple treatments (P<0.001). Oesophageal perforation was documented in 
23patients (4%) at the time of stent placement and 3 patients (2%) after 
LASER.  
Survival for all patients receiving EPT was 40% at 6 months, 17% at 12 
months, 10% at 18 months and 6 % at 24 months, suggesting benefits from 
EPT even in patients with advanced disease. 
Conclusion: Despite potential differences between patients receiving 
different types of EPT, there is evidence for regional variation in the 
approaches used. However, evidence from this population based cohort 
demonstrates that appropriate use of intervention may provide prolonged 
palliation for patients with upper gastrointestinal cancer.  
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THE ROLE OF VITAMIN C IN THE PATHOGENESIS OF 
BARRETT￿S OESOPHAGUS 
1Fountoulakis, A., 
1Martin, I.G., White, K.L.M., 
2Cade, J., 
1Sue-Ling, H.M. 
and *Wild C.P. 
Molecular Epidemiology Unit, Division of Epidemiology and Health 
Services Research, 
1Academic Unit of Surgery and 
2Nuffield Institute for 
Health, 
 School of Medicine, University of Leeds, Leeds LS2 9JT, UK. 
Barrett￿s oesophagus (BO) is a condition where the squamous epithelium of 
the lower oesophagus is replaced by a metaplastic, specialised columnar type. 
BO arises as a complication of gastro-oesophageal reflux disease and is 
associated with a 30-125 fold increased risk of oesophageal adenocarcinoma 
(OA) development. Over the last 30 years the incidence of OA has increased 
dramatically, implicating environmental factors in the aetiology of this 
disease. Recent epidemiological studies have linked low fruit and vegetable 
consumption and dietary antioxidants with increased OA risk. The aim of this 
study was to test the hypothesis that levels of antioxidants are reduced in the 
plasma and modified mucosa of BO patients.  
Following ethical approval, blood samples and endoscopic biopsies 
(squamous, Barrett￿s and gastric mucosa) were obtained from 57 BO and an 
equal number of age and sex matched control (blood sampled only) patients. 
BO patients also completed food frequency questionnaires. Plasma 
concentrations of vitamins A, C and E were measured by HPLC and 
compared between BO and control patients.  Within BO patients, levels of 
vitamin C were also compared across different mucosal sites. 
Histology revealed intestinal metaplasia in 45, gastric metaplasia in 9 and 
dysplasia in 3 of the BO patient group. Total vitamin C (and ascorbic acid 
levels) were significantly (p<0.05) reduced in the plasma of patients with 
intestinal metaplasia (8.3 [5.6-11.2] µ g vit. C/ml {median with interquartile 
range}), compared with matched control patients (10.4 [6.4-14.5] µ g vit. C 
/ml). There was no significant difference in the plasma levels of vitamins A 
and E between these two groups. 
A positive association was identified between total vitamin C levels and 
dietary intake of vitamin C in BO patients. Tissue levels of total vitamin C 
(and ascorbic acid) were significantly (p<0.05) lower in Barrett￿s  (96.0 
[75.6-116.6] µ g vit. C/g) compared with matched squamous mucosa  (118.3 
[88.5-156.3] vit. C µ g/g), whereas levels measured in Barrett￿s and gastric 
(81.6 [68.0-102.7]µ g/g) mucosa were similar.  
In conclusion, levels of vitamin C are reduced in the plasma and specialised 
columnar epithelia of BO patients. This antioxidant may play an important 
role in the pathogenesis and neoplastic progression of BO, perhaps by 
modulating the extent of oxidative stress and associated DNA damage in 
oesophageal mucosa. 
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THE ROLE OF DNA DAMAGE IN THE DEVELOPMENT OF 
BARRETT￿S OESOPHAGUS AND OESOPHAGEAL 
ADENOCARCINOMA 
Olliver J.R*., Hardie L.J., 
1Clark, G.W.B., Dexter S.,
2Chalmers, D. and Wild 
C.P. 
Molecular Epidemiology Unit and 
1Department of Surgery, School of 
Medicine, University of Leeds and 
2Gastroenterology Unit, Leeds General 
Infirmary, Leeds LS2 9JT, UK 
Oesophageal adenocarcinoma (ADC) is increasing in incidence in the 
Western world. Survival is poor with patients having a median survival time 
of less than a year. The strongest risk factor (30-125 fold increase) for the 
development of ADC is the presence of the precursor condition, Barrett￿s 
oesophagus (BO), where the squamous epithelium is replaced by a 
metaplastic specialised columnar epithelium, usually in response to gastro-
oesophageal reflux (GOR). 
Molecular changes which occur during the development of ADC may prove 
useful as markers to assess the progression from BO to ADC (Bani-Hani et 
al, 2000; JNCI 92;1316-1321). It is our hypothesis that these molecular 
changes may result from DNA damage caused by GOR. This study therefore 
aims to examine whether GOR is associated with an elevation in DNA 
damage in BO. Ethical approval was granted for BO and control patients to 
be recruited from local dyspepsia and Barrett￿s surveillance endoscopy 
clinics. For each BO patient, biopsies were collected from normal squamous 
oesophageal, gastric and Barrett￿s mucosa. Control patients had only normal 
squamous tissue sampled. In addition, questionnaires were completed 
detailing reflux history, medication, smoking and alcohol intake. Biopsies 
were subject to DNA damage analysis using the alkaline ￿Comet￿ assay to 
measure levels of DNA strand breaks (SB). 
Preliminary findings indicate a significantly raised (P<0.001) mean level of 
SBs in BO tissue (28.32+5.70 {mean % tail DNA+SD}, N=18) when 
compared with matched squamous mucosa (19.29+6.61) from the same 
patient. Out of 18 Barrett￿s patients, 16 showed higher levels of DNA 
damage in BO tissue compared to squamous mucosa. In contrast there was no 
significant difference (P>0.05) in the mean levels of SBs when comparing 
BO (28.32+5.70) and gastric mucosa (26.71+9.01), perhaps reflecting the 
histological similarity between these tissues. Somewhat surprisingly, levels 
of SBs in the squamous tissue of control patients (25.73+5.87) were higher 
than those in the squamous tissue of BO patients (19.29+6.61).  There was no 
association between DNA damage levels and age, sex, Helicobactor pylori
infection, alcohol or smoking. 
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This is consistent with a role for oxidative DNA damage in the development 
of ADC.
This work is supported by Yorkshire Cancer Research.
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ADJUVANT TREATMENT  OF DUKES￿S  C COLORECTAL 
CANCER WITH  6 CYCLES (10 WEEKS) OF MODIFIED 
DeGRAMONT 5-FLUOROURACIL/ FOLINIC ACID PRODUCES  
DISEASE FREE AND OVERALL SURVIVAL COMPARABLE WITH  
6 MONTHS OF TREATMENT 
Russell D. Petty*, Les Samuel and Jim Cassidy. 
Department of Oncology, ANCHOR UNIT, Aberdeen Royal Infirmary, 
Aberdeen. 
Randomised controlled trials have established the benefit of adjuvant 
treatment with 5-Fluorouracil/Folinic acid (5-FU/FA) for patients with 
Duke￿s C Colorectal cancer (CRC)
1. However, the optimal scheduling of 
treatment remains to be determined. Clinical trials have determined that 6 
months of treatment with  a bolus or infusional regimen produces results 
similar to longer periods
1.Breast cancer trials have collected the most data on 
adjuvant chemotherapy. Overall, for  the adjuvant treatment of node positive 
breast cancer, meta-analyses suggest that the benefit is similar to that seen in 
Dukes C CRC with 5-FU/FA- an approximately 25-30% reduction in the 
relative risk of recurrent disease and death
2. Randomised controlled trials  in 
breast cancer have  shown that treatment with  3 or 4 cycles of treatment ( 6-9 
weeks) provides similar disease free  survival (DFS) and overall survival 
(OS) compared with longer periods of treatment
3. Such results may be 
applicable to the adjuvant treatment of Duke￿s C CRC. 
Here we present the results of a consecutive cohort of 42 patients with 
curative resection of Dukes C CRC treated  adjuvantly with 6 cycles (10 
weeks) of modified De Gramont chemotherapy (FA 200mg/m
2 2 hour 
infusion day 1 and 2, 5-FU  600mg/m
2bolus  day 1 and 2, , 5-FU 600mg/m
2
22 hour infusion day 1 and 2, repeated every 2 weeks). All patients 
commenced treatment between January 1998 and February 1999 within 6 
weeks of surgery- 25(60%)  were male 17(40%) female, median age 62 years 
(range 39-78). All patients were WHO performance status 0-1, there were 
27(65%) rectal cancers, 8(19%) sigmoid cancers, 5(11%)  left colon cancers,  
and 2(5%) right colon cancers.  There were 37(88%) patients with Dukes C1, 
5(12%) Dukes C2, and  there  were 1-4 lymph nodes involved in 27(64%), 5 
or more lymph nodes involved in 13(31%). The treatment was well tolerated 
with grade 3 toxicity (mostly diarrhoea) in 11 (26%) and grade 4 in only 
3(7%). 
Median follow up for patients still alive was  37 months. Estimated 3 year 
DFS was 71.6% and OS was 77.7% (life table analysis). Kaplan-Meier 
analysis reveals that median DFS and OS have not yet been reached.  These 
results are comparable with those found in randomised trials of 6 months of 
5-FU/FA with both infusional and bolus type regimens
1. Confirmation of 
these results in larger studies (we are currently collecting data on a larger 
cohort) may allow  the routine use of  shorter (10 weeks) periods of adjuvant 
treatment  with 5-FU/FA  for Duke￿s C CRC- this is likely to be beneficial  
for quality of life outcomes, toxicities of treatment  and  in terms of 
pharmacoeconomics. Such data  may also prove applicable to adjuvant 
treatment with new 5-FU oral pro-drugs, and in 5-FU combination 
chemotherapy. 
1.Polychronis A and Haller D 2000, The Effective Management of  CRC p3. 
2.Early Breast Cancer Trialist Collaborative Group 1992 Lancet 339 (8785): 
71.
3. Hortobgyi GN, Seminars in Oncology2001 28(5) Suppl 16:33. 
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LOCALLY ADVANCED PANCREATIC CANCER TREATED WITH 
RADIATION AND 5-FLUOROURACIL,  
S. Mawdsley*
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2.
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Introduction: Current approaches to the treatment of pancreatic cancer are 
disappointing, with few patients surviving longer than 12 months from the 
time of diagnosis.  This report describes the survival and local relapse rates of 
patients with locally advanced pancreatic carcinoma, treated at Mount 
Vernon Hospital with 5-fluorouracil (5FU) chemoradiation.  Locally 
advanced was defined by the extent of lymphadenopathy or invasion of 
adjacent organs, without evidence of distant metastases. 
Methods: Between 1994 and 2000, 24 patients were treated with radiation 
and 5-fluorouracil (5-FU).  All patients were WHO performance status 0-2 
and had pre-treatment radiological staging with CT or MRI.  The 
radiotherapy was CT planned and the standard dose prescribed was 45Gy in 
25 fractions over 5 weeks.  5-FU was given as a 60 minutes infusion on days 
1-5 and 29-33 of the radiotherapy, at 350mg/m
2, following low dose folinic 
acid.  Actuarial survival, local control and toxicity rates according to WHO 
criteria, were assessed for the group. 
Results: The median survival was 12 months, with a 48% 1-year survival and 
a 29% 2 year survival.  The median time to progression was 8 months.  The 
treatment was well tolerated and all patients achieved 100% compliance.   
There were no grade 3-4 haematological toxicities.  30% experienced 
diarrhoea but in all cases this was mild (grade 1-2).  58% experienced emesis 
and in 3 patients this was grade 3, however no interruption of treatment was 
required.  In terms of radiological tumour response, 5 patients (22%) had a 
complete response, 10 patients (45%) demonstrated partial tumour shrinkage 
and a further 3 additional patients had radiological stable disease.  The 
majority of patients (92%) experienced a symptomatic improvement.   
Conclusion: Chemoradiation with 5-fluorouracil can produce effective local 
control with symptomatic improvement in patients with localised carcinoma 
of the pancreas.  This is not at the expense of considerable toxicity, either late 
or acute.  
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THE GASTRIC CANCER 5 (GC5) STUDY: ANTIBODY RESPONSE 
AND SIDE EFFECT PROFILE OF G17DT 500mcg IN POST 
GASTRIC CANCER RESECTION PATIENTS 
EJ Dickson*, E Cowan, RC Stuart. 
University Dept of Surgery, Glasgow Royal Infirmary, Glasgow. 
AIM: Gastrin has a trophic effect on gastrointestinal epithelium as part of its 
normal physiological function, and gastrin 17 in particular stimulates the 
growth of gastrointestinal (GI) cancer cell lines. The aims of the GC5 study 
were to determine the anti-gastrin antibody response to G17DT 500mcg 
(Aphton Corps) and to evaluate patient tolerance at this higher dose. 
METHODS: Gastrin 17 linked to the diphtheria toxoid (G17DT) was 
administered as a 500mcg intramuscular injection at weeks 0, 2 and 6 to 
seven patients who had previously undergone potentially curative gastric 
cancer resection. Approval was obtained from the local Ethics Committee. 
G17DT antibody titres were measured over the follow up period (median 419 
days, range 391-463 days). Patients underwent CT scanning for assessment 
of tumour recurrence on 3 occasions. 
RESULTS: All seven patients achieved an antibody response (median 177.2 
units, range 33.9-313.7 units) which remained quantifiable in five patients at 
the end of the follow-up period, although the third dose was administered to 
one patient only. Four patients developed an abscess at the injection site and 
all seven patients reported minor to severe local side effects (pain, 
immobility, and tenderness). Based on CT scanning no patients had tumour 
recurrence during this period. The median length of time from surgery to 
most recent follow-up is 1148 days (range 790 to 1716 days). All patients are 
currently disease-free. 
CONCLUSIONS: At this dosage schedule G17DT is an effective method of 
producing a sustained anti-gastrin antibody response at the expense of 
unacceptable tolerance. However the high dose of 500mcg may be utilised in 
conjunction with chemotherapy as combination therapy, as the 
chemotherapeutic agents are anti-inflammatory and may suppress injection 
site reactions. Of note, there is no evidence of local nor systemic recurrence 
in any patient. 
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IMPAIRED POST-OPERATIVE NEUTROPHIL LEUCOCYTOSIS 
AND ACUTE COMPLICATIONS FOLLOWING SHORT COURSE 
PREOPERATIVE RADIOTHERAPY FOR OPERABLE RECTAL 
CANCER 
Hartley A*
1, Giridharan S
1, Srihari N
1, McConkey C
2 and Geh JI
1
1Cancer Centre, Queen Elizabeth Hospital, Birmingham.B15 2TH  
2Clinical Trials Unit, CRC Institute of Cancer Studies, Birmingham 
Introduction:  In the Dutch Colorectal Cancer Group Trial the 180-day 
mortality was increased in patients undergoing total mesorectal excision 
(TME) more than 3 days after the completion of short course preoperative 
radiotherapy (SCPRT). A similar relationship between time from the first day 
of SCPRT to surgery (overall treatment time (OTT)) and acute complications 
was observed in a recent retrospective audit. One proposed explanation for 
these findings and the relationship of acute complications with age and 
radiation volume is suppression of the neutrophil leucocytosis normally seen 
following abdominal surgery. This study aimed to determine the relationship 
between acute complications within 3 months of SCPRT and perioperative 
absolute neutrophil counts (ANC). 
Method:  A SCPRT database of 176 patients treated in 1998 and 1999 was 
used. Preoperative (preop) ANC (48 hours before surgery) and postoperative 
(postop) ANC (48 hours after surgery) were obtained from haematology 
archives. A two sample Wilcoxan test was used to compare preop ANC, 
postop ANC and the ratio postop ANC/preop ANC (ANC ratio) in patients 
with and without complications. The relationship between these parameters 
and OTT, age and radiotherapy field length was examined. 
Results: Due to pre-clerking preop ANC was only available in 83  (47%) 
patients. Postop ANC was performed in 128 (73%) patients. ANC ratio was 
calculable in 72 (41%) patients. There was no significant association between 
acute complications and preop ANC (p=0.25) or postop ANC (p=0.45). ANC 
ratio was significantly higher in patients without complications (p=0.02). 
There was no clear relationship between ANC ratio and OTT, field length or 
age. Logistic regression including ANC ratio, OTT, age and field length 
showed that ANC ratio (p=0.02) and OTT (p=0.06) might be significant 
factors. 
Conclusions: In this retrospective study there appears to be a relationship 
between the magnitude of postop neutrophil leucocytosis and the absence of 
acute complications following SCPRT. However, this study is limited by a 
majority of preoperative full blood counts being taken many days before 
surgery at pre-clerking. 
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PATIENTS￿ ATTITUDES TO CEA TESTING IN COLORECTAL 
CANCER FOLLOW-UP: A PILOT STUDY.  
NL Fernie
*, MJ Mackean, Edinburgh Cancer Centre, Western General 
Hospital, Crewe Road South, Edinburgh EH4 2XU. 
The routine use of CEA testing in the follow-up of patients who have 
undergone curative resection +/- adjuvant treatment for colorectal cancer 
remains a controversial issue. Unlike many other cancers, where metastatic 
disease is invariably incurable, there is a small but significant chance of 
detecting localised liver or lung metastases, resection of which can result in 
cure
1. Approximately 25% of patients with up to 3 resectable liver metastases 
are long term survivors. Randomised trials have, however, failed to show an 
overall survival benefit from CEA testing. The cost-effectiveness of this 
practice has also been called into question, given the common nature of the 
disease and the expense of diagnosing a recurrence that is often incurable
2.
The attitudes of colorectal cancer patients to follow up and its effect on their 
quality of life have been previously studied. In general patients reported a 
strong preference for follow-up, even if it did not lead to earlier detection of 
recurrence and despite any anxieties provoked by the follow-up visit
3. The 
attitudes of patients towards specific investigations, notably the CEA blood 
test, have not been formally examined. 
In this ongoing pilot study, patients￿ attitudes to and preferences for CEA 
testing are being assessed using a questionnaire. 12 patients have been 
recruited so far, 7 male and 5 female. Median age 61-70 years. 8 of the 
patients questioned were within 2 years of their surgery and all were within 5 
years of resection. 9 of the 12 patients admitted to worrying to some degree 
about cancer recurrence. 2 of the patients questioned had had CEA detected 
recurrences. 6 patients worried a little or somewhat about their CEA result 
after the clinic whilst 6 were not at all concerned. 11 patients would accept 
the test even if there were a significant risk of a false positive or false 
negative result. All patients recruited wished to know if an asymptomatic 
recurrence were detected in this way, even if incurable. 
Early results of this pilot study of patient preferences for CEA testing 
indicate that an overwhelming majority of patients are in favour of the test. 
This is despite uncertainties as to the accuracy of the result and the generally 
low cure rate of recurrences, even when detected early in this setting. It is our 
view that in deciding whether to test for CEA we should be guided our 
patients￿ preferences in addition to published data on survival and health 
economics.  
1.  Registry of Hepatic Metastases (1988) Resection of the liver for 
colorectal carcinoma metastases. Surgery 103: 278 
2.  Nelson RL (1995) Postoperative evaluation of patients with colorectal 
cancer. Sem Oncol 22 (5): 488   
3.  Stiggelbout AM, de Haes JCJM, Vree R et al (1997) Follow-up of 
colorectal cancer patients: Quality of life and attitudes towards follow-up. Br
J Cancer 75 (6): 914   
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SELECTIVE PRE-OPERATIVE RADIOTHERAPY FOR RECTAL 
CANCER, A RETROSPECTIVE AUDIT OF RESULTS 
Mark A Potter*, Catriona McLean, Hamish A Phillips 
Departments of Surgery* and Oncology Wetern General Hospital, Edinburgh 
Preoperative radiotherapy for rectal cancer reduces local recurrence but has a 
limited impact on overall survival. A selective policy of preoperative 
radiotherapy for patients at high risk of local recurrence is pursued at our 
institution. Indications for short course preoperative radiotherapy are low 
cancers, perirectal infiltration on imaging, tethering and anterior cancers 
close to the prostate. The results for 1996 ￿ 2000 have been audited.  
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